Financial Gravity Asset Management’s Pacira BioSciences PCRX Stock Holding History

Financial Gravity Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-204	Closed	-$54K	–	1291
2019 Q4	$54K	Buy	204 +1	+0.5%	+$42	0.04%	603
2019 Q3	$8K	Hold	203	–	–	0.01%	641
2019 Q2	$9K	Buy	203 +3	+2%	+$127	0.01%	621
2019 Q1	$7K	Buy	+200	New	+$7.81K	0.01%	630
2018 Q3	$10K	Buy	+200	New	+$8.64K	0.01%	578

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Financial Gravity Asset Management's PCRX Position: Q1 2020 in Review

Financial Gravity Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 204 shares — an estimated $54K sold.

Financial Gravity Asset Management first reported a position in PCRX in Q3 2018 and held it in 5 quarters. The position peaked at $54K in Q4 2019. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

Financial Gravity Asset Management reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
Financial Gravity Asset Management sold 204 Pacira BioSciences shares in Q1 2020, an estimated $54K.
Financial Gravity Asset Management first reported a position in Pacira BioSciences in Q3 2018 and held it in 5 quarters.
Financial Gravity Asset Management's Pacira BioSciences position peaked at $54K in Q4 2019.
226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Financial Gravity Asset Management's 13F filing for Q1 2020, filed 12 May 2020.